The Single-Dose Tolerability and PK/PD Study of Recombinant (Expressed by Pichia Pastoris) Human Serum Albumin/Human Granulocyte-Colony Stimulating Factor(I) Fusion Protein for Injection (GW003) in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 21 Aug 2017
At a glance
- Drugs Balugrastim (Primary)
- Indications Neutropenia
- Focus Adverse reactions
- Sponsors Jiangsu T-mab BioPharma
- 15 Aug 2017 Status changed from recruiting to completed.
- 12 Jan 2017 Planned End Date changed from 1 Jan 2017 to 1 Mar 2017.
- 12 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Feb 2017.